1. Home
  2. EYPT vs HROW Comparison

EYPT vs HROW Comparison

Compare EYPT & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EyePoint Pharmaceuticals Inc.

EYPT

EyePoint Pharmaceuticals Inc.

HOLD

Current Price

$16.10

Market Cap

1.5B

Sector

Industrials

ML Signal

HOLD

Logo Harrow Inc.

HROW

Harrow Inc.

HOLD

Current Price

$47.21

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EYPT
HROW
Founded
1987
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.4B
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
EYPT
HROW
Price
$16.10
$47.21
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
8
Target Price
$29.60
$68.86
AVG Volume (30 Days)
1.1M
535.4K
Earning Date
11-05-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$42,339,000.00
$250,042,000.00
Revenue This Year
N/A
$39.05
Revenue Next Year
N/A
$40.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
47.83
52 Week Low
$3.91
$20.85
52 Week High
$19.11
$51.30

Technical Indicators

Market Signals
Indicator
EYPT
HROW
Relative Strength Index (RSI) 60.28 60.58
Support Level $15.97 $44.48
Resistance Level $19.11 $47.90
Average True Range (ATR) 0.96 2.46
MACD 0.11 0.82
Stochastic Oscillator 46.36 68.13

Price Performance

Historical Comparison
EYPT
HROW

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.

Share on Social Networks: